Skip to main content

INTERMITTENT ANDROGEN DEPRIVATION THERAPY PLUS COMPREHENSIVE STEREOTACTIC BODY RADIOTHERAPY FOR OLIGOMETASTATIC HORMONE SENSITIVE PROSTATE CANCER (CROP): MATURE RESULTS OF A PROSPECTIVE TRIAL

In brief

After radiation and intermittent hormone therapy, 39% remained off treatment

In this single-arm trial of 89 men, 39% were alive with hormone-sensitive prostate cancer and off androgen deprivation therapy at last follow-up, after a median 74.7 months. At five years, 22.8% had developed treatment-resistant disease, while 6.7% experienced severe adverse events; without a comparison group, the benefit over other treatment strategies remains unknown.

Journal
International journal of radiation oncology, biology, physics (Q1)
Published
16 November 2026
Study design
Phase 1 (first-in-human) trial
Evidence level
Level 4, Very Low (CEBM 4)
Authors
Patrick Cheung, Chia-Lin Tseng, Hans Chung, William Chu, Danny Vesprini, Stanley Liu, et al.
PMID
43039250
DOI
10.1016/j.ijrobp.2026.10.052

Why clinicians should know about it

Abstract

PURPOSE: This phase I/II single-arm trial assessed the tolerability and efficacy of stereotactic body radiotherapy (SBRT) to all tumours plus intermittent androgen deprivation therapy (ADT) in patients with oligometastatic hormone sensitive prostate cancer (HSPC). Primary endpoint was the incidence of grade 3+ SBRT induced adverse events (AE's), including radiotherapy induced bone fractures. Secondary endpoints included failure-free survival (FFS), cumulative incidence of developing castration resistant prostate cancer (CRPC), and overall survival (OS). METHODS: Eligible patients had synchronous or metachronous oligometastases (≤ 5 metastases, with ≤ 3 metastases in any one organ system) identified on conventional imaging. SBRT was delivered to all lesions, along with 1 year of ADT before stopping. Intermittent ADT (using 1 year cycles) was restarted when the prostate specific antigen (PSA) reached > 10 ng/mL, if new metastases developed, or earlier at the discretion of the physician. SBRT could be delivered to any new oligometastases that developed while off ADT in conjunction with restarting ADT. RESULTS: Eighty-nine evaluable patients with 171 metastases were enrolled. Median follow-up was 74.7 months. Thirty-three patients (37.1%) had synchronous disease presentation. Six patients (6.7%) experienced grade 3 AE's (5 patients with vertebral fractures and 1 patient with urinary tract obstruction). The 5-year cumulative incidence of restarting ADT and developing CRPC were 59.7% and 22.8% respectively. Five-year FFS and OS were 15.2% and 78.2% respectively. Higher PSA nadir after SBRT and 1 year of ADT was significantly associated with developing subsequent CRPC and worse OS. At time of last follow-up, 35 patients (39.3%) were alive with HSPC and not on ADT. CONCLUSION: SBRT and intermittent ADT for oligometastatic HSPC was safe and resulted in favourable long-term outcomes. A small proportion of patients did not progress in any way after SBRT and 1 year of ADT.

Abstract as published, via PubMed.

View on PubMedFull text at the publisherOpen in the app

For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.